SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline, Human Genome Sciences, Inc. Get Fast Review For Lupus Drug

August 19, 2010 | 
1 min read
LONDON, Aug 19 (Reuters) - A keenly awaited new lupus drug from GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences Inc (HGSI.O) will get a priority review from U.S. regulators, potentially clearing the way for its approval by mid-December.
Regulatory Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector
Vaccines
FDA Clears Updated COVID-19 Shots From Pfizer, Moderna, Novavax—But With Restrictions
August 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Susan Monarez speaking to a senator at her confirmation hearing as CDC director
Policy
Monarez Fired From Top CDC Spot Following Friction Over New COVID-19 Vaccine Policy
August 28, 2025
 · 
3 min read
 · 
Heather McKenzie
A pit crew working on a race car
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
 · 
2 min read
 · 
Tristan Manalac